Back to Home

Drug Pricing

Expert articles and analysis related to drug pricing.

200 articles•Last 30 Days

AI Summary — Last 30 Days

CMS is pushing drug-pricing reform deeper into managed care operations, with proposals targeting Medicare Advantage provider directory accuracy, PBM transparency, and drug-cost reduction—moves that would increase plan accountability and may reshape MA-PD contracting, formulary strategy, and pharmacy network economics for VBC organizations (AHA summary). At the same time, Medicare market disruption is accelerating: 4.3 million beneficiaries are slated to lose MA drug or stand-alone Part D plans at the end of 2026, creating near-term retention, risk-coding, medication adherence, and care-continuity challenges for ACOs, MA plans, and provider groups managing senior populations (KFF analysis). Medicaid and specialty-drug affordability are also moving toward model-based solutions, with GLP-1 access under the BALANCE Model and the 340B rebate dispute signaling a broader shift from unit-price fights toward budget predictability, pharmacy-channel control, and outcomes-linked access for high-cost therapies.

Related Articles

95ALN

How Changes in Drug Price Policy Affect Your Wallet and Part D Plan

How Changes in Drug Price Policy Affect Your Wallet and Part D Plan  Kiplinger

KiplingerOct 25, 2026
95ALN

PBM influence is only growing, American Medical Association report finds

The 10 largest PBMs are also part of a company that owns a health plan.

Healthcare BrewOct 22, 2026
95ALN

Brand Drugmakers Raise Median Net Launch Price of New Drugs 35% In Just Three Years

Brand Drugmakers Raise Median Net Launch Price of New Drugs 35% In Just Three Years  AHIP

AHIPOct 22, 2026
95ALN

Inside the 340B Rebate Pilot Standoff: Court, Congress, Drugmakers

Pharmaceutical CommerceOct 22, 2026
95ALN

Administration Finalizes Medicare Part B International Reference Pricing Model

Administration Finalizes Medicare Part B International Reference Pricing Model  Health Affairs

Health AffairsOct 22, 2026
95ALN

Administration Finalizes Medicare Part B International Reference Pricing Model

Administration Finalizes Medicare Part B International Reference Pricing Model  Health Affairs

Health AffairsOct 22, 2026
95ALN

AHA urges court to reject drug industry intervention in 340B rebate program case

AHA urges court to reject drug industry intervention in 340B rebate program case  American Hospital Association

AHAOct 21, 2026
95ALN

Price of new drugs up 35% since 2022: 6 things hospital leaders should know

Price of new drugs up 35% since 2022: 6 things hospital leaders should know  Becker's Hospital Review

Becker's Hospital ReviewOct 21, 2026
95ALN

The U.S. Pays Triple What Other Countries Pay for Drugs. Here’s What the Evidence Says About Fixing It.

The U.S. Pays Triple What Other Countries Pay for Drugs. Here’s What the Evidence Says About Fixing It.  AcademyHealth

AcademyHealthOct 21, 2026
95ALN

Analysis finds net launch price for new prescription drugs climbed 35% from 2022 to 2025

Analysis finds net launch price for new prescription drugs climbed 35% from 2022 to 2025  American Hospital Association

AHAOct 20, 2026